Is Benitec Biopharma Stock a Good Investment?
Benitec Biopharma Investment Advice | BNTC |
- Examine Benitec Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Benitec Biopharma's leadership team and their track record. Good management can help Benitec Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Benitec Biopharma's business and its evolving consumer preferences.
- Compare Benitec Biopharma's performance and market position to its competitors. Analyze how Benitec Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Benitec Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Benitec Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Benitec Biopharma Ltd stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Benitec Biopharma Ltd is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Benitec Biopharma Stock
Researching Benitec Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 46.0% of the company shares are held by institutions such as insurance companies. The book value of Benitec Biopharma was currently reported as 4.68. The company recorded a loss per share of 5.51. Benitec Biopharma last dividend was issued on the 18th of November 2019. The entity had 1:17 split on the 26th of July 2023.
To determine if Benitec Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Benitec Biopharma's research are outlined below:
| Benitec Biopharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Benitec Biopharma to Participate in Upcoming Investor Conferences in December |
Benitec Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Benitec Biopharma Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Benitec Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Benitec Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Benitec Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2024-11-11 | 2024-09-30 | -0.55 | -0.4753 | 0.0747 | 13 | ||
2023-02-13 | 2022-12-31 | -0.11 | -0.2 | -0.09 | 81 | ||
2022-11-10 | 2022-09-30 | -0.18 | -0.47 | -0.29 | 161 | ||
2022-09-02 | 2022-06-30 | -0.28 | -0.62 | -0.34 | 121 | ||
2021-09-20 | 2021-06-30 | -0.93 | -0.57 | 0.36 | 38 | ||
2023-09-21 | 2023-06-30 | -3.23 | -2.83 | 0.4 | 12 | ||
2024-09-19 | 2024-06-30 | -0.49 | -1.32 | -0.83 | 169 |
Know Benitec Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Benitec Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Benitec Biopharma Ltd backward and forwards among themselves. Benitec Biopharma's institutional investor refers to the entity that pools money to purchase Benitec Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lion Point Capital, Lp | 2024-09-30 | 39 K | Longwood Capital Partners Llc | 2024-09-30 | 29.8 K | Blackrock Inc | 2024-06-30 | 28 K | Northern Trust Corp | 2024-09-30 | 24.8 K | Citadel Advisors Llc | 2024-09-30 | 14.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11.2 K | Gamma Investing Llc | 2024-09-30 | 6.5 K | Ubs Group Ag | 2024-06-30 | 2 K | Tower Research Capital Llc | 2024-06-30 | 891 | Suvretta Capital Management, Llc | 2024-06-30 | 1.7 M | Hhg Plc | 2024-06-30 | 900.8 K |
Benitec Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 215.39 M.Market Cap |
|
Benitec Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.46) | (0.48) |
Determining Benitec Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Benitec Biopharma is a good buy. For example, gross profit margin measures Benitec Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Benitec Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of Benitec Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Benitec Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Benitec Biopharma's management manipulating its earnings.
Evaluate Benitec Biopharma's management efficiency
Benitec Biopharma has return on total asset (ROA) of (0.496) % which means that it has lost $0.496 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9168) %, meaning that it created substantial loss on money invested by shareholders. Benitec Biopharma's management efficiency ratios could be used to measure how well Benitec Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, Benitec Biopharma's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 54.3 M, whereas Other Current Assets are forecasted to decline to about 480.1 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.64 | 11.06 | |
| Tangible Book Value Per Share | 11.64 | 11.06 | |
| Enterprise Value Over EBITDA | 0.94 | 0.99 | |
| Price Book Value Ratio | 0.62 | 0.59 | |
| Enterprise Value Multiple | 0.94 | 0.99 | |
| Price Fair Value | 0.62 | 0.59 | |
| Enterprise Value | -21.1 M | -20 M |
Understanding the operational decisions made by Benitec Biopharma management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.879 |
Basic technical analysis of Benitec Stock
As of the 1st of December, Benitec Biopharma shows the Downside Deviation of 3.57, risk adjusted performance of 0.0533, and Mean Deviation of 3.28. Benitec Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Benitec Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Benitec Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Benitec Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Benitec Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Suvretta Capital Management, Llc over a week ago Acquisition by Suvretta Capital Management, Llc of 3076 shares of Benitec Biopharma at 10.22 subject to Rule 16b-3 | ||
Suvretta Capital Management, Llc over a week ago Acquisition by Suvretta Capital Management, Llc of 1570 shares of Benitec Biopharma at 9.73 subject to Rule 16b-3 | ||
Mehta Kishan over three months ago Insider Trading | ||
Smith Edward F over six months ago Acquisition by Smith Edward F of 12000 shares of Benitec Biopharma subject to Rule 16b-3 | ||
Megan Boston over six months ago Acquisition by Megan Boston of 200004 shares of Benitec Biopharma at 5.21 subject to Rule 16b-3 | ||
Buchi J Kevin over six months ago Acquisition by Buchi J Kevin of 35000 shares of Benitec Biopharma subject to Rule 16b-3 | ||
Megan Boston over a year ago Purchase by Megan Boston of 25907 shares of Benitec Biopharma | ||
Jerel Banks over a year ago Acquisition by Jerel Banks of 356900 shares of Benitec Biopharma subject to Rule 16b-3 |
Benitec Biopharma's Outstanding Corporate Bonds
Benitec Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Benitec Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Benitec bonds can be classified according to their maturity, which is the date when Benitec Biopharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Benitec Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Benitec Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0533 | |||
| Market Risk Adjusted Performance | 1.76 | |||
| Mean Deviation | 3.28 | |||
| Semi Deviation | 3.42 | |||
| Downside Deviation | 3.57 | |||
| Coefficient Of Variation | 1701.32 | |||
| Standard Deviation | 4.69 | |||
| Variance | 21.95 | |||
| Information Ratio | 0.0294 | |||
| Jensen Alpha | 0.246 | |||
| Total Risk Alpha | (0.52) | |||
| Sortino Ratio | 0.0386 | |||
| Treynor Ratio | 1.75 | |||
| Maximum Drawdown | 29.78 | |||
| Value At Risk | (4.52) | |||
| Potential Upside | 7.89 | |||
| Downside Variance | 12.72 | |||
| Semi Variance | 11.73 | |||
| Expected Short fall | (4.00) | |||
| Skewness | 1.47 | |||
| Kurtosis | 4.48 |
| Risk Adjusted Performance | 0.0533 | |||
| Market Risk Adjusted Performance | 1.76 | |||
| Mean Deviation | 3.28 | |||
| Semi Deviation | 3.42 | |||
| Downside Deviation | 3.57 | |||
| Coefficient Of Variation | 1701.32 | |||
| Standard Deviation | 4.69 | |||
| Variance | 21.95 | |||
| Information Ratio | 0.0294 | |||
| Jensen Alpha | 0.246 | |||
| Total Risk Alpha | (0.52) | |||
| Sortino Ratio | 0.0386 | |||
| Treynor Ratio | 1.75 | |||
| Maximum Drawdown | 29.78 | |||
| Value At Risk | (4.52) | |||
| Potential Upside | 7.89 | |||
| Downside Variance | 12.72 | |||
| Semi Variance | 11.73 | |||
| Expected Short fall | (4.00) | |||
| Skewness | 1.47 | |||
| Kurtosis | 4.48 |
Consider Benitec Biopharma's intraday indicators
Benitec Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Benitec Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Benitec Biopharma Corporate Filings
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 7th of November 2024 Other Reports | ViewVerify |
Benitec Stock media impact
Far too much social signal, news, headlines, and media speculation about Benitec Biopharma that are available to investors today. That information is available publicly through Benitec media outlets and privately through word of mouth or via Benitec internal channels. However, regardless of the origin, that massive amount of Benitec data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Benitec Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Benitec Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Benitec Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Benitec Biopharma alpha.
Benitec Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Benitec Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Benitec Biopharma Corporate Management
| Michael Graham | Founding Scientist and Head of Discovery | Profile | |
| Bryan Dulhunty | Chief Officer | Profile | |
| Claudia Kloth | Senior Manufacturing | Profile | |
| Craig Lewis | Chief Adviser | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Benitec Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.